Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes
Sheila Weiss Smith(University of Maryland, Baltimore), Amy J. Davidoff, Masayo Sato(Tokyo Women's Medical University), S. D. Gore(Johns Hopkins University), Diane McNally(University of Maryland, Baltimore), Ke Xu(Nanjing University), Maria R. Baer(University of Maryland, Baltimore)
Cited by 40
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764